FDA

The Centre for Cellular and Molecular Platforms, known as C-CAMP, which stands as one of India’s leading hubs for bioscience innovation and one of the most significant bio-incubators in the country, has formed a strategic alliance with the University of […]

This year marks the third iteration of Synquizitive, Syngene International’s annual science quiz, which engaged students from 200 government schools across Bengaluru, Dakshin Kannada, and Hyderabad. This initiative was carried out in collaboration with Biocon Foundation and Agastya International Foundation.

Leading the forefront of medical technology, Fujifilm India has introduced the mikoto Colon Model, a groundbreaking simulation system for endoscopy training. This sophisticated medical training tool aims to transform the learning process in the field of endoscopy. Compact and highly

Biocon Biologics, under the umbrella of Biocon, has been honored yet again as an Asia IP Elite for the year 2024 by Intellectual Asset Management (IAM), a prominent authority on intellectual property. This recognition marks the eighth year running that

Bio-Techne Corporation has announced that Asuragen, one of its brands, has released a cutting-edge assay designed for the precise detection of ESR1 mutations. These genetic alterations in the ESR1 gene are associated with HR+ metastatic breast cancer. The research-use-only assay

Virax Biolabs Group Limited, a pioneering biotech entity specializing in immune response detection and viral disease diagnostics, has announced the formation of a non-exclusive distribution alliance with Tebubio, a French enterprise, to extend the reach of its ImmuneSelect Research Use

Crown Aesthetics, a branch of Crown Laboratories renowned in the dermatologic and aesthetics medical device sector, has announced the release of the SkinPen Precision Elite. This innovative device, cleared by the FDA, sets a new standard in microneedling technology with

On Monday, December 9th, science and technology leaders from the UK and Switzerland finalized an update to their pivotal science and research agreement, setting the stage for collaboration on vital contemporary challenges such as advancing public health and transitioning to

Johnson & Johnson has disclosed new findings from the phase 3 CARTITUDE-4 trial, highlighting a single dose of Carvykti (ciltacabtagene autoleucel, cilta-cel) markedly boosts rates of minimal residual disease (MRD) negativity (10-5) among patients with relapsed or refractory multiple myeloma

Endo, Inc., a versatile specialty pharmaceutical company committed to turning insights into therapies that improve lives, has announced the initiation of shipping for its doxycycline for injection, USP 100 mg/vial, an AP-rated alternative to Doxy 100. “We are excited to